Sleeve lobectomy versus pneumonectomy for non-small cell lung cancer: a meta-analysis

• Published in: World journal of surgical oncology Vol. 10; no. 1; p. 265
• Main Authors: Shi, Woda, Zhang, Wei, Sun, Haoliang, Shao, Yongfeng
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 11.12.2012; BioMed Central; BMC
• Subjects: Analysis; Cancer; Carcinoma, Non-Small-Cell Lung - mortality; Carcinoma, Non-Small-Cell Lung - surgery; Clinical trials; Clothing and dress; Health aspects; Humans; Lung cancer; Lung cancer, Non-small cell; Lung cancer, Small cell; Lung Neoplasms - mortality; Lung Neoplasms - surgery; Meta-analysis; Models, Statistical; Mortality; Neoplasm Recurrence, Local; Non-small cell lung cancer; Odds Ratio; Oncology, Experimental; Patient Selection; Pneumonectomy; Pneumonectomy - methods; Pneumonectomy - mortality; Postoperative Complications - epidemiology; Pulmonary arteries; Sleeve lobectomy; Studies; Survival Rate; Treatment Outcome
• ISSN: 1477-7819; 1477-7819
• DOI: 10.1186/1477-7819-10-265

It is controversial that whether sleeve lobectomy (SL) should be promoted more worthy than pneumonectomy (PN) in suitable patients. We searched all studies that had been published in English from PUBMED and Embase which compared the short-term and long-term outcomes of SL and pneumonectomy (PN) in patients with non-small cell lung cancer (NSCLC). Nineteen studies met our criteria with a combined total of 3878 subjects, of which 1316 (33.9%) underwent SL and 2562 (66.1%) underwent PN. The odds ratio was 0.50 (95% CI: 0.34-0.72) for postoperative mortality, 1.17 (95% CI: 0.82-1.67) for postoperative complications, 0.78 (95% CI: 0.47-1.29) for locoregional recurrences. The risk difference for 1-, 3-, 5- year was 0.11 (95% CI: 0.07-0.14), 0.15 (95% CI: 0.06-0.24), 0.15 (95% CI: 0.09-0.20),respectively. The pooled hazard ratio was 0.63 (95% CI: 0.56-0.71) in favor of SL group. SL is more worthy to be done than PN in suitable patients with less mortality and better long-term survival.